ongitudinal non-interventional observational study on Adherence, safety and tolerability of AVANZ® in adults and GRAZAX® and SLIToneULTRA® in adults and children (5 – 17 years) in patients with allergic Rhinoconjunctivitis in GErmany

• Conditions: J30.1; J30.3; Allergic rhinitis due to pollen; Other allergic rhinitis

• Registration Number: DRKS00005069
• Lead Sponsor: ALK-Abelló Arzneimittel GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07-04
• Study Completion: 2018-05-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 2571

Inclusion Criteria

Routine treatment with specific immunotherapy (AVANZ®/GRAZAX®/SLIToneULTRA®)

Exclusion Criteria

Contraindications of specific immunotherapy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adherence / persistence during the planned 3-year course of specific immunotherapy quantified by the proportion of completers considering treatment discontinuations due to adverse events or reasons definitely not related to treatment, frequency of re-prescriptions.

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability during the planned 3-year course of treatment, application of measures to increase compliance, predictive factors for adherence/persistence, correlation with therapeutic effect, patient questionnaire for health care research